Celldex Therapeutics Inc - Asset Resilience Ratio

Latest as of March 2026: 81.32%

Celldex Therapeutics Inc (CLDX) has an Asset Resilience Ratio of 81.32% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how liquid is Celldex Therapeutics Inc's working capital to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

$415.73 Million

Cash + Short-term Investments

Total Assets

$511.25 Million

All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2009–2025)

This chart shows how Celldex Therapeutics Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see CLDX total assets.

Liquid Assets Composition Over Time

This chart breaks down Celldex Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore investment intensity of Celldex Therapeutics Inc to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	$0.00	0%
Short-term Investments	$415.73 Million	81.32%
Total Liquid Assets	$415.73 Million	81.32%

Asset Resilience Insights

Very High Liquidity: Celldex Therapeutics Inc maintains exceptional liquid asset reserves at 81.32% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company has significant short-term investments, indicating active treasury management.

Celldex Therapeutics Inc Industry Peers by Asset Resilience Ratio

Compare Celldex Therapeutics Inc's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
argenx NV ADR NASDAQ:ARGX	Biotechnology	15.95%
Madrigal Pharmaceuticals Inc NASDAQ:MDGL	Biotechnology	62.31%
Shanghai RAAS Blood Products Co Ltd Class A SHE:002252	Biotechnology	2.03%
Halozyme Therapeutics Inc NASDAQ:HALO	Biotechnology	12.71%
Tubize-Fin BR:TUB	Biotechnology	2.50%
Aurinia Pharmaceuticals Inc NASDAQ:AUPH	Biotechnology	33.23%
Nanobiotix NASDAQ:NBTX	Biotechnology	4.71%
Innovita Biological Technology Co. Ltd. A SHG:688253	Biotechnology	65.12%

Annual Asset Resilience Ratio for Celldex Therapeutics Inc (2009–2025)

The table below shows the annual Asset Resilience Ratio data for Celldex Therapeutics Inc.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	84.00%	$489.70 Million	$582.98 Million	-3.96pp
2024-12-31	87.96%	$696.92 Million	$792.34 Million	+4.87pp
2023-12-31	83.09%	$386.88 Million	$465.63 Million	+4.98pp
2022-12-31	78.11%	$275.52 Million	$352.74 Million	-4.90pp
2021-12-31	83.01%	$369.11 Million	$444.65 Million	+19.16pp
2020-12-31	63.85%	$150.59 Million	$235.84 Million	+20.78pp
2019-12-31	43.07%	$52.95 Million	$122.93 Million	-1.67pp
2018-12-31	44.74%	$69.71 Million	$155.81 Million	+13.33pp
2017-12-31	31.41%	$99.14 Million	$315.62 Million	-7.02pp
2016-12-31	38.43%	$147.31 Million	$383.36 Million	-26.08pp
2015-12-31	64.51%	$217.78 Million	$337.58 Million	-5.25pp
2014-12-31	69.76%	$173.02 Million	$248.01 Million	+31.28pp
2013-12-31	38.49%	$133.58 Million	$347.10 Million	-8.56pp
2012-12-31	47.05%	$59.06 Million	$125.54 Million	+4.79pp
2011-12-31	42.26%	$41.41 Million	$97.99 Million	+6.05pp
2010-12-31	36.21%	$39.81 Million	$109.94 Million	+18.08pp
2009-12-31	18.13%	$25.45 Million	$140.36 Million	--

pp = percentage points

About Celldex Therapeutics Inc

NASDAQ:CLDX USA Biotechnology

Market Cap

$3.02 Billion

Market Cap Rank

#4900 Global

#1656 in USA

Share Price

$38.51

Change (1 day)

-1.71%

52-Week Range

$22.58 - $44.87

All Time High

$271.65